Talks with farmers today, govt says it has an 'open mind'

HARIKISHAN SHARMA
& RAAKHI JAGGA
New Delhi/Ludhiana, Feb 11

AS PUNJAB FARMER unions, who have called for a protest march to Delhi on Tuesday, announced they would wait for word on the outcome of talks Monday over their demands, Union agriculture minister Arjun Munda said on Sunday that the Centre is always ready to talk with an "open mind".

Munda said, "One round of talks has already been held. It was a good discussion. The next meeting will be held. Talks will be held again. We will resolve it through dialogue if there is any issue."

Munda, along with Union minister Piyush Goyal, and minister of state Nityanand Rai, will hold the second round of talks with the protesting farmers in Chandigarh on Monday.

"There may be differences between the government's thinking and farmers' demands but we will sit and find a solution with care and patience. We are ready to talk with khule mann (an open mind) to allay any misunderstanding," Munda said.

"Kitna hum kar sakte hain, kitna kisanon ke hit mein rahega, donon ko milkar hi samadhan nikalna hai (How much can we do, and what will be in the interest of farmers, a solution has to be found by sitting together)," he said.

One of the key demands of the farmers is a legal guarantee of minimum support price (MSP). The Centre has announced MSP for 22 mandated crops on the basis of the recommendations of the Commission for Agricultural Costs & Prices (CACP).

On July 18, 2022, the Centre had formed a committee to deliberate on several issues including making the MSP more "effective and transparent". The committee was formed in the wake of the November 2021 announcement by the Prime Minister on his government's intention to withdraw three farm laws – Farmers Produce Trade and Commerce (Promotion and Facilitation) Act, 2020; Farmers (Empowerment and Protection) Agreement on Price Assurance and Farm Services Act, 2020; and the Essential Commodities (Amendment) Act, 2020 – following a protest by farm unions. The unions were also demanding a legal guarantee of MSP based on the Swaminathan Commission's C2+50% Formula.

The committee, headed by former agriculture secretary Sanjay Agrawal, held six "main" meetings and 31 sub-group meetings/workshops. It is yet to submit its report.

On Sunday, Sarwan Singh Pandher, coordinator of the Kisan Mazdoor Morcha, said farmers affiliated to the KMM and Samyukta Kisan Morcha (non-political) will set out from Punjab and gather at Fatehgarh Sahib by Monday afternoon.

Any decision to march ahead, he said, will be taken following the outcome of the talks. "Tractors in thousands will march from Punjab's different parts and reach midway by Monday afternoon itself... Farmers will sleep overnight in their tractors by the roadside and will march towards Delhi as per the outcome of the talks," Pandher said.

Barricades put up at the Ghazipur border ahead of Tuesday's farmers' march. PRAVEEN KHANNA

TMC declines seat-sharing talks with Congress panel

MANOJ CG
New Delhi, January 11

THE POSSIBILITY OF a seat-sharing pact between the Congress and the Trinamool Congress (TMC) in West Bengal receded further on Thursday with the TMC signalling it would not meet the five-member national alliance committee of the Congress that has been holding talks with parties of the INDIA alliance to work out seat adjustments in states. Sources in the TMC said the party had already conveyed its offer to the Congress. The Congress panel — comprising Ashok Gehlot, Bhupesh Baghel, Mukul Wasnik, Salman Khurshid, and Mohan Prakash — has held one round of discussions with parties such as the Samajwadi Party (SP), Shiv Sena (UBT), NCP, AAP, and RJD. The TMC, sources said, had offered Malda Dakshin and Baharampur to the Congress.

West Bengal Congress president Adhir Ranjan Chowdhury has already rejected the offer saying the party had won those seats on its own in 2019 fighting against the TMC and the BJP, and that the Congress does not need any "grace or generosity" from Mamata to win those two seats. "I can fight it alone against Banerjee and the BJP because I have proved it. My colleague and I can fight in both the seats on our own. We don't require any grace from Banerjee to retain the two seats," Chowdhury told *The Indian Express* earlier.

Pawar: EC 'snatched' NCP from its founders

PRESS TRUST OF INDIA
Pune, February 11

SENIOR POLITICIAN SHARAD Pawar on Sunday said the Election Commission's decision to allot the NCP name and symbol to the Ajit Pawar-led group was "surprising" as the poll body has "snatched" the party from the hands of its founders and gave it to others.

He also said the programme and ideology are important for the people while a symbol is useful for a limited period.

In a setback to Sharad Pawar, the Election Commission on February 6 recognised the Ajit Pawar faction as the real Nationalist Congress Party (NCP) and also allotted the party symbol 'clock' to the group led by him.

"I am confident that people will not support the EC ruling against which we have approached the SC," Sharad Pawar said. The EC not only snatched our symbol but also handed over our party to others, he said. "The EC snatched the party from the hands of those who founded and built it and gave it to others; such a thing never happened before in the country," said Pawar, who founded the NCP in 1999 after breaking away from Congress.

RPN Singh, Sudhanshu Trivedi on BJP's list of RS candidates

THE BJP ON SUNDAY named 14 candidates for the upcoming Rajya Sabha polls including former Union minister RPN Singh and Sudhanshu Trivedi — the only outgoing MP renominated by the party. Union minister Rajeev Chandrasekhar, who represents Karnataka in Rajya Sabha, and BJP chief spokesperson and media head Anil Baluni, the outgoing MP from Uttarakhand, have been replaced with fresh faces amid indications that they may contest the upcoming Lok Sabha polls. Some new names, including Narayansa K Bhandage from Karnataka and Devendra Pratap Singh from Chhattisgarh, are little known but have been rewarded for their years of hard work for the party, something the current BJP leadership has often recognised. —PTI

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Initial public offer of Equity Shares (as defined below) on the main board of the Stock Exchanges (defined below) in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended

PUBLIC ANNOUNCEMENT

Akums

AKUMS DRUGS AND PHARMACEUTICALS LIMITED

(Please scan this QR code to view the DRHP)

Our Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of 'Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("**RoC**"). Our Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Registered Office: 304, Mohan Place, LSC Saraswati Vihar, Delhi – 110 034, India
Corporate Office: Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area, Phase 1, Delhi – 110 083, India
Telephone: + 91 11 6904 1000; **Contact person:** Dharamvir Malik, Company Secretary and Compliance Officer
E-mail: cs@akums.net; **Website:** www.akums.in; **Corporate Identity Number:** U24239DL2004PLC125888

THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 6,800 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 18,598,365 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, COMPRISING UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY SANJEEV JAIN, UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY SANDEEP JAIN (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO 14,306,435 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

THIS OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE [●]% AND [●]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.

OUR COMPANY, IN CONSULTATION WITH THE BRLMs, MAY CONSIDER A PRIVATE PLACEMENT OF UP TO 20% OF THE FRESH ISSUE OR SUCH OTHER AMOUNT AS MAY BE ALLOWED UNDER APPLICABLE LAW FOR CASH CONSIDERATION AGGREGATING UP TO ₹ 1,360 MILLION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE MINIMUM OFFER SIZE (COMPRISING THE FRESH ISSUE SO REDUCED BY THE AMOUNT RAISED FROM THE PRE-IPO PLACEMENT, AND THE OFFER FOR SALE) SHALL CONSTITUTE AT LEAST 10% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 2 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [●], AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF [●], A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE AND NSE (TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.

In case of any revision to the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Managers, for reasons to be recorded in writing, may extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("**SCSBs**"), other Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**") ("**QIB Portion**"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price ("**Anchor Investor Portion**"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA accounts and UPI ID (in case of UPI Bidders) (as defined hereinafter), in which case the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or under the UPI Mechanism, as applicable to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "*Offer Procedure*" on page 415 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares pursuant to the Offer and has filed the DRHP dated February 10, 2024 with the Securities and Exchange Board of India ("**SEBI**") on February 11, 2024.

Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made available to the public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the Book Running Lead Managers ("BRLMs"), i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and www.ambit.co, respectively. Our Company hereby invites the public to provide comments on the DRHP filed with SEBI, with respect to disclosures made therein. The public is requested to send a copy of the comments to SEBI, to the Company Secretary & Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein below. All comments must be received by SEBI and/or our Company and/or the Company Secretary & Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5.00 p.m. on the 21st day from the aforesaid date of filing the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the section titled "*Risk Factors*" of the RHP, once available, carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" on page 27 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after a red herring prospectus ("**RHP**") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the Stock Exchanges.

The liability of the members of our Company is limited. For details of the share capital and capital structure of our Company and the name of the signatories to its Memorandum of Association and the number of shares subscribed by them of our Company, please see "*Capital Structure*" on page 72 of the DRHP. For details of the main objects of our Company as contained in its Memorandum of Association, please see "*History and Certain Corporate Matters*" on page 204 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
ICICI Securities	AXIS CAPITAL	citi	AMBIT Acumen at work	LINKIntime
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India **Tel:** +91 22 6807 7100 **E-mail:** akums.ipo@icicisecurities.com **Investor grievance e-mail:** customercare@icicisecurities.com **Website:** www.icicisecurities.com **Contact Person:** Namrata Ravasia / Harsh Thakkar **SEBI Registration No.:** INM000011179	**Axis Capital Limited** 1st Floor, Axis House, C-2 Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai 400 025, Maharashtra, India **Tel:** +91 22 4325 2183 **E-mail:** akums.ipo@axiscap.in **Investor grievance e-mail:** complaints@axiscap.in **Website:** www.axiscapital.co.in **Contact Person:** Akash Aggarwal / Jigar Jain **SEBI Registration No.:** INM000012029	**Citigroup Global Markets India Private Limited** 1202, 12th Floor, First International Financial Centre, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 098, Maharashtra, India **Tel:** +91 22 6175 9999 **E-mail:** akums.ipo@citi.com **Website:** www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm **Investor Grievance ID:** investors.cgmib@citi.com **Contact Person:** Abhishek Mawandiya **SEBI Registration Number:** INM000010718	**Ambit Private Limited** Ambit House, 449, Senapati Bapat Marg, Lower Parel, Mumbai 400 013 Maharashtra, India **Tel:** + 91 22 6623 3030 **E-mail:** akums.ipo@ambit.co **Investor Grievance E-mail:** customerservicemb@ambit.co **Website:** www.ambit.co **Contact person:** Siddhesh Deshmukh **SEBI registration number:** INM000010585	**Link Intime India Private Limited** C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India **Tel:** +91 810 811 4949 **E-mail:** akumsdrugs.ipo@linkintime.co.in **Website:** www.linkintime.co.in **Investor Grievance ID:** akumsdrugs.ipo@linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **SEBI Registration Number:** INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **AKUMS DRUGS AND PHARMACEUTICALS LIMITED**

On behalf of the Board of Directors
Sd/-
Dharamvir Malik
Company Secretary & Compliance Officer

Place: New Delhi
Date: February 11, 2024

AKUMS DRUGS AND PHARMACEUTICALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP with SEBI on February 11, 2024. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the BRLMs, i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and www.ambit.co, respectively. Potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "*Risk Factors*" of the RHP, once filed. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision and must rely on their own examination of our Company and the Offer, including the risks involved.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of securities in the United States.

Adfactors

NOTICE AND ADVERTISEMENT FOR THE EXTRA-ORDINARY GENERAL MEETING OF EQUITY SHAREHOLDERS.

Notice is hereby given that Mr. Prem Anand shareholder of M/s Everlast Fibre Glass Products Private Limited ("**Company**") had served special notice to board of directors of the Company pursuant to Section 100, 115, 152 and 169 of the Companies Act, 2013 along with relevant rules made thereunder, on **16.01.2023** for calling extra ordinary general meeting.

The Board of Directors of the Company have failed to issue notice for calling extra ordinary general meeting within a period of 21 days from date of submission of special notice. Hence, considering the lack of action taken by Board of Directors of the Company, requisitionist Mr. Prem Anand is hereby issuing notice to call extra-ordinary general meeting of the Shareholders of the Company for the purpose of considering, and if thought fit, approving with or without modification the Appointment of Mr. Prem Anand (DIN: 01611721), Mr. Srikanth Ankem (DIN 01611825) and Mrs. Sobha Anand (DIN 01809931) as directors of the Company and Removal of Ms. Jayalakshmi and Mrs. V N K Menon from the position of directorship of the Company.

In pursuance of the said notice meetings of the Shareholders of the Company will be held on **11.03.2024** at **11:00 A.M** at **Villa # 3, Ezzy Corinth, Gubbi Cross, Kothanur, Bengaluru KA 560077 IN**, at which time and place the said Shareholders are requested to attend.

Copies of the said notice along with explanatory statement under section 100, section 152, section 169 and section 115 read with section 102 of the Companies Act, 2013 ("the Act") along with applicable rules can be obtained free of charge from Mr. Prem Anand at Villa # 3, Ezzy Corinth, Gubbi Cross, Kothanur, Bengaluru, Karnataka, India - 560077, by any Shareholder on any working days, except Saturdays, Sundays and public holidays, during the business hours prior to the date of the meeting and the same shall be furnished within one day of the requisition being made. The Persons entitled to attend and vote at the meetings of Shareholders may vote in person or through authorised representative, or through Proxy, provided that all proxies in the Form MGT-11, are sent through email at **anand.prem@gmail.com** or deposited at place of the meeting at Villa # 3, Ezzy Corinth, Gubbi Cross, Kothanur, Bengaluru, Karnataka, India - 560077, not later than 48 hours before the scheduled time of the commencement of respective meetings.

Forms of proxy can be obtained free of charge at Villa # 3, Ezzy Corinth, Gubbi Cross, Kothanur, Bengaluru, Karnataka, India - 560077.

For Everlast Fibre Glass Products Private Limited
Mr. Prem Anand
Shareholder

Date: 12.02.2024
Place : Bengaluru

Pritika Auto Industries Limited

Regd. Office: Plot No. C-94, Phase-VII Industrial Focal Point, S.A.S. Nagar Mohali Punjab – 160055
CIN: L45208PB1980PLC046738, Phone No. 0172-5008900
Email Id: compliance@pritikaautoindustries.com website: www.pritikaautoindustries.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2023

Particulars	Unaudited			Rs. in Lakh		Audited
	Quarter ended			Nine Months ended		FY ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
Total Income from Operations	7115.60	9392.24	7809.11	26033.75	27460.07	36323.52
Net Profit before Tax, Exceptional and/or Extraordinary items	489.31	691.61	326.17	1906.37	1763.03	2157.30
Net Profit before tax after Exceptional and/or Extraordinary items	489.31	691.61	326.17	1906.37	1763.03	2157.30
Net Profit for the period after tax	398.46	475.10	286.35	1426.22	1299.39	1569.43
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	399.05	474.05	286.63	1426.21	1296.91	1550.99
Paid up Equity Share Capital	3067.25	1773.45	1773.45	3067.25	1773.45	1773.45
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	14357.47
Earnings Per Share (of Rs. 02/- each) (for continuing and discontinued operations) Basic	0.33	0.43	0.32	1.19	1.47	1.77
Diluted	0.29	0.43	0.32	1.04	1.47	1.77
Note 1: Additional Information on Standalone Financial Results pursuant to Reg. 47 (1) (b)						
Total income from operations	7105.73	8032.64	6690.93	25936.08	23891.30	31508.27
Profit before Tax	335.95	565.12	286.15	1501.91	1478.75	1758.44
Profit after Tax	282.25	383.20	221.94	1125.35	1054.19	1242.42

2. The above results for the quarter and nine months ended 31st Dec. 2023, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th February, 2024 . The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015.
3. The Company is in business of manufacturing of components for automotive industry and hence only one reportable operating segment as per 'Ind-AS - 108 : Operating Segments'.
4. The Hon'ble NCLT Chandigarh Bench, vide its order dated 04/12/2023 has sanctioned the Scheme of Arrangement between Pritika Industries Limited (the Demerged Company) and Pritika Auto Industries Limited (the Resulting Company) approving Demerger and vesting of the "Automotive/Tractor/Engineering Components Business Undertaking" of Pritika Industries Limited as a going concern with Pritika Auto Industries Limited.
5. The figures for quarter ended 31/12/2023 and Nine months ended 31/12/2023 has been arrived giving effect of the figures of Demerged undertaking of Pritika Industries Limited. Hence, these figures are not comparable with figures from previous quarters, the Nine months ended 31/12/2022 and year ended 31/03/2023.
6. The above is an extract of detailed format of unaudited results filed with stock exchange. The full format of quarterly/nine months Financial Results and notes are available on website of BSE Ltd. (www.bseindia.com) and NSE Ltd (www.nseindia.com) and on the company's website (www.pritikaautoindustries.com).

Place: Mohali
Date: 10.02.2024

By order of the Board
For Pritika Auto Industries Limited
Harpreet Singh Nibber, Managing Director DIN: 00239042

'राकांपा को संस्थापकों से छीनकर निर्वाचन आयोग ने दूसरों को दे दिया'

पुणे,11 फरवरी (भाषा)।

वरिष्ठ नेता शरद पवार ने रविवार को कहा कि अजित पवार के नेतृत्व वाले गुट को राष्ट्रवादी कांग्रेस पार्टी (राकांपा) नाम और चुनाव चिह्न आवंटित किए जाने का निर्वाचन आयोग का फैसला हैरान करने वाला है। पवार ने साथ ही कहा कि निर्वाचन आयोग ने उन लोगों के हाथों से पार्टी छीन ली जिन्होंने इसे बनाया और इसे (आयोग ने) दूसरों को दे दिया।

उन्होंने कहा कि लोगों के लिए कार्यक्रम और विचारधारा अहम है जबकि किसी चुनाव चिह्न की उपयोगिता एक सीमित समय के लिए होती है। उन्होंने कहा, मुझे भरोसा है कि लोग निर्वाचन आयोग के फैसले का समर्थन नहीं करेंगे। इसके खिलाफ हमने उच्चतम न्यायालय का दरवाजा खटखटाया है। शरद पवार ने कहा कि निर्वाचन आयोग ने न केवल हमारा चुनाव चिह्न छीना, बल्कि हमारी पार्टी भी दूसरों को दे दी। पवार ने राकांपा की स्थापना 1999 में की थी। उन्होंने कहा, निर्वाचन आयोग ने उन लोगों के हाथों से पार्टी छीन ली जिन्होंने इसे बनाया, आगे बढ़ाया। ऐसा पहले कभी नहीं हुआ।

जब से भाजपा सत्ता में आई, तब से उसके किसी नेता को ईडी का सामना नहीं करना पड़ा है : पवार

पुणे, 11 फरवरी (भाषा)।

वरिष्ठ नेता शरद पवार ने रविवार को दावा किया कि भाजपा के सत्ता में आने के बाद से पार्टी के किसी भी नेता को प्रवर्तन निदेशालय (ईडी) की कार्रवाई का सामना नहीं करना पड़ा है।

निर्वाचन आयोग द्वारा हाल में उनके भतीजे अजित पवार के नेतृत्व वाले गुट को 'मूल' राष्ट्रवादी कांग्रेस पार्टी (राकांपा) के रूप में मान्यता देने और पार्टी का चुनाव चिह्न 'घड़ी' आवंटित करने पर शरद पवार ने कहा कि देश में ऐसी स्थिति कभी नहीं देखी गई है और लोग ऐसे फैसले का समर्थन नहीं करेंगे। आयोग ने शरद पवार के नेतृत्व वाले समूह के लिए पार्टी का नाम 'राष्ट्रवादी कांग्रेस पार्टी–शरदचंद्र पवार' आवंटित किया है।

'भुजबल को नए ओबीसी राजनीतिक संगठन का नेतृत्व करना चाहिए'

मुंबई, 11 फरवरी (भाषा)।

वंचित बहुजन आघाडी (वीबीए) के प्रमुख प्रकाश आंबेडकर ने रविवार को महाराष्ट्र के मंत्री छगन भुजबल को नए ओबीसी संगठन में उसके नेता के तौर पर शामिल होने की सलाह दी और कहा कि अगर भुजबल ऐसा करते हैं तो वे उन्हें समर्थन देंगे। वीबीए, अब विपक्षी इंडिया गठबंधन का हिस्सा है।

महाराष्ट्र के खाद्य एवं आपूर्ति मंत्री भुजबल, उप मुख्यमंत्री अजित पवार नीत राष्ट्रवादी कांग्रेस पार्टी (राकांपा) से हैं जो राज्य में शिवसेना और भाजपा गठबंधन सरकार में साझेदार है।

महाराष्ट्र में मंत्री होने के बावजूद अन्य पिछड़ा वर्ग (ओबीसी) के प्रमुख नेता भुजबल ने मराठा आरक्षण को लेकर राज्य सरकार के रुख का विरोध किया है। भीमराव आंबेडकर के पोते प्रकाश आंबेडकर ने सोशल मीडिया मंच 'एक्स'पर पोस्ट किया कि ओबीसी नेताओं ने राज्य में नया दल बनाने की घोषणा की है। मेरा छगन भुजबल को सलाह है कि वह इस संगठन का नेतृत्व करें। वीबीए सामाजिक और राजनीतिक रूप से इसका समर्थन करेगा।

उन्होंने कहा कि मुझे उम्मीद है कि भुजबल वीबीए की सलाह पर गौर करेंगे। भुजबल हाल में उस वक्त चर्चा में रहे थे, जब उन्होंने मराठा समुदाय के लोगों को कुनबी (ओबीसी) प्रमाण पत्र देने के फैसले का विरोध किया था। उन्होंने सरकार के इसे मराठा समुदाय को पीछे के दरवाजे से ओबीसी आरक्षण देना करार दिया था। खबरों के मुताबिक, कई ओबीसी नेताओं ने हाल में इस मुद्दे पर भुजबल से मुलाकात की थी।

महाराष्ट्र के खाद्य एवं आपूर्ति मंत्री भुजबल, उप मुख्यमंत्री अजित पवार नीत राष्ट्रवादी कांग्रेस पार्टी (राकांपा) से हैं जो राज्य में शिवसेना और भाजपा गठबंधन सरकार में साझेदार है। उन्होंने कहा कि मुझे उम्मीद है कि भुजबल वीबीए की सलाह पर गौर करेंगे। भुजबल हाल में उस वक्त चर्चा में रहे थे, जब उन्होंने मराठा समुदाय के लोगों को कुनबी (ओबीसी) प्रमाण पत्र देने के फैसले का विरोध किया था।

अभ्यार्थियों को आज नियुक्ति पत्र बांटेंगे प्रधानमंत्री

जनसत्ता ब्यूरो
नई दिल्ली, 11 फरवरी।

प्रधानमंत्री नरेंद्र मोदी सोमवार को केंद्र सरकार के विभागों में नियुक्त किए गए एक लाख से अधिक अभ्यर्थियों को नियुक्ति पत्र वितरित करेंगे। इस अवसर पर प्रधानमंत्री यहां एकीकृत परिसर 'कर्मयोगी भवन' के प्रथम चरण की आधारशिला भी रखेंगे।

यह परिसर मिशन कर्मयोगी के विभिन्न स्तंभों के बीच सहयोग और तालमेल को बढ़ावा देगा। प्रधानमंत्री कार्यालय ने यह जानकारी दी। कार्यालय के मुताबिक प्रधानमंत्री 'वीडियो कांफ्रेंस' के माध्यम से एक लाख से अधिक अभ्यर्थियों को नियुक्ति पत्र वितरित करेंगे।

बिहार में वोट पाने के लिए कर्पूरी ठाकुर को दिया भारत रत्न : उद्धव ठाकरे

मुंबई, 11 फरवरी (भाषा)।

शिवसेना (यूबीटी) के अध्यक्ष उद्धव ठाकरे ने रविवार को दावा किया कि आगामी लोकसभा चुनाव में बिहार से वोट हासिल करने के लिए नरेंद्र मोदी की सरकार ने कर्पूरी ठाकुर को भारत रत्न से सम्मानित किया है। शिवसेना के यहां एकत्रित कार्यकर्ताओं को संबोधित करते हुए ठाकरे ने दावा किया कि भारतीय जनता पार्टी (भाजपा) के पूर्ववर्ती संगठन भारतीय जन संघ ने सरकारी नौकरियों में अन्य पिछड़े वर्ग (ओबीसी) को 26 फीसद आरक्षण देने के ठाकुर के फैसले का विरोध किया था।

"प्रपत्र सं. आईएनसी–26"
(कंपनी (निगमन) नियम, 2014 के नियम 30 के अनुसरण में)
कंपनी का रजिस्ट्रीकृत कार्यालय एक राज्य से दूसरे राज्य में अंतरित करने के लिए समाचार पत्र में प्रकाशित किया जाने वाला विज्ञापन
केन्द्रीय सरकार क्षेत्रीय निदेशक के समक्ष उत्तरी क्षेत्र, कंपनी अधिनियम, 2013 की धारा 13 की उपधारा (4) और कंपनी (निगमन) नियम, 2014 के नियम 30 के उपनियम (5) के खंड (अ) के मामले में
और
विकैसेट एडवाइजर्स इंडिया प्राईवेट लिमिटेड जिसका रजिस्ट्रीकृत कार्यालय नंबर : दूसरा फ्लोर, प्लॉट नं. 37, सरस्वती कुंज, सैक्टर 54 गोल्फ कोर्स रोड, अर्बन एस्टेट, गुरुग्राम–122001, इंडिया में स्थित है
.....याचिकाकर्ता कंपनी

आम जनता को यह सूचना दी जाती है कि यह कंपनी केन्द्रीय सरकार के समक्ष कंपनी अधिनियम, 2013 की धारा 13 के अधीन आवेदन फाइल का प्रस्ताव करती है जिसमें कंपनी का रजिस्ट्रीकृत कार्यालय "हरियाणा राज्य" से "महाराष्ट्र राज्य" कंपनी रजिस्ट्रार, मुम्बई के अधिकार क्षेत्र में स्थानांतरित करने के लिए तारीख 12 जनवरी, 2024 को आयोजित असाधारण सामान्य बैठक में पारित विशेष संकल्प के संदर्भ में कंपनी के मेमोरेंडम ऑफ एसोसिशन में संशोधन की पुष्टि की मांग की गई है।

कंपनी के रजिस्ट्रीकृत कार्यालय के प्रस्तावित स्थानांतरण से यदि किसी व्यक्ति का हित प्रभावित होता है तो वह व्यक्ति या तो निवेशक शिकायत प्ररुप फाइल कर एमसीए–21 पोर्टल (www.mca.gov.in) में शिकायत दर्ज कर सकता है या एक शपथ पत्र जिसमें उनके हित का प्रकार और उसके विरोध का कारण उल्लिखित हो के साथ अपनी आपत्ति क्षेत्रीय निदेशक उत्तरी क्षेत्र, को इस सूचना के प्रकाशन की तारीख से 14 दिनों के भीतर बी–2 विंग, द्वितीय तल, पंडित दीनदयाल अत्योदय भवन, सीजीओ कॉम्प्लेक्स, नई दिल्ली–110003 पते पर पंजीकृत डाक द्वारा भेज सकता है या सुपुर्द कर सकते है और इसकी प्रति आवेदक कंपनी को उनके उपरोक्त रजिस्ट्रीकृत कार्यालय के पते पर भी भेजेगा।
दूसरा फ्लोर, प्लॉट नं. 37, सरस्वती कुंज, सैक्टर 54 गोल्फ कोर्स रोड, अर्बन एस्टेट, गुरुग्राम–122001, इंडिया
कृते की ओर से
विकैसेट एडवाइजर्स इंडिया प्राईवेट लिमिटेड
हस्ता./–
दिनांक : 12.02.2024 दीपक ईश्वरदास राठी
स्थान : गुरुग्राम (निदेशक)
डीआईएन : 02096135
पता : जी–3, 2/1, गार्डन व्यू सीएचएस, प्लॉट नं. 8, सेक्टर 7, सानपाड़ा नवी मुम्बई महाराष्ट्र–400705, इंडिया

प्ररूप संख्या आईएनसी–26
{कम्पनी (निगमन) नियम, 2014 के नियम 30 के अनुसरण में}
केन्द्र सरकार, क्षेत्रीय निदेशक, उत्तरी क्षेत्र, नई दिल्ली के समक्ष
कंपनी अधिनियम, 2013 की धारा 13 की उपधारा (4) और कंपनी (निगमन) नियम, 2014 के नियम 30 (5) (ए) के मामले में
और
अनोखी संस एग्रो इंडिया प्राइवेट लिमिटेड
(CIN:U74899DL1994PTC060046)
जिसका पंजीकृत कार्यालय : **278, कटरा पेरान, तिलक बाजार, खारी बावली, दिल्ली–110006** में हैं, के मामले में
....आवेदक कंपनी/याचिकाकर्ता

एतदद्वारा सार्वजनिक सूचना दी जाती है कि यह कंपनी केन्द्रीय सरकार के समक्ष कंपनी अधिनियम, 2013 की धारा 13(4) के अधीन आवेदन का प्रस्ताव करती है, जिसमें कंपनी का पंजीकृत कार्यालय **"राष्ट्रीय राजधानी क्षेत्र दिल्ली"** से **"हरियाणा राज्य"** में स्थानांतरित करने के लिए **शनिवार, 03 फरवरी 2024** को आयोजित असाधारण सामान्य बैठक में पारित विशेष प्रस्ताव के संदर्भ में कंपनी के मेमोरेंडम ऑफ एसोसिएशन में बदलाव की पुष्टि करने की मांग की गई है।

कंपनी के पंजीकृत कार्यालय के प्रस्तावित स्थानांतरण से यदि किसी व्यक्ति का हित प्रभावित होता है तो वह व्यक्ति या तो **निवेशक शिकायत प्ररूप फाइल कर एमसीए–21 पोर्टल (www.mca.gov.in) में शिकायत दर्ज कर सकता है** या एक शपथ पत्र जिसमें उनके हित का प्रकार और उसके विरोध का कारण उल्लिखित हो, के साथ अपनी आपत्ति क्षेत्रीय निदेशक को इस सूचना के प्रकाशन की तारीख से चौदह (14) दिनों के भीतर **क्षेत्रीय निदेशक, उत्तरी क्षेत्र, कारपोरेट कार्य मंत्रालय, बी–2 विंग, दूसरा तल, पंडित दीनदयाल अंत्योदय भवन, सीजीओ कॉम्पलैक्स, नई दिल्ली–110003** पर पंजीकृत डाक द्वारा भेज सकता है और इसकी प्रति आवेदक कंपनी को उनके निम्नलिखित पंजीकृत कार्यालय पते पर भी भेजें।
278, कटरा पेरान, तिलक बाजार, खारी बावली, दिल्ली–110006
आवेदक के लिए और आवेदक की ओर से
अनोखी संस एग्रो इंडिया प्राइवेट लिमिटेड
हस्ता/–
प्रवेश कुमार गर्ग (निदेशक)
डीआईएन : 00245911
दिनांक : 12.02.2024 45, पूर्वी मार्ग, वसंत विहार,
स्थान : दिल्ली नई दिल्ली–110057

HINDUJA HOUSING FINANCE
हिंदुजा हाउसिंग फाइनेंस लिमिटेड
कॉर्पोरेट कार्यालय : क्रमांक 167–169, द्वितीय तल, अन्ना सलाई, सैदापेट, चेन्नई–600015
शाखा कार्यालय: 418, चौथी मंजिल, पर्ल ओमेक्स टावर–2, नेताजी सुभाष प्लेस, नई दिल्ली–110034
चल वस्तुओं को हटाने के लिए सार्वजनिक सूचना
को,
1. श्री राम राम
फ्लैट नं. एसएफ–02, प्लॉट नं. 16, खसरा नंबर 355, संत नगर, लोनी, गाजियाबाद–201102
2. श्रीमती सीमा देवी
प्लॉट नंबर 33, संत नगर, लोनी, गाजियाबाद–210102

जबकि अधोहस्ताक्षरी मैसर्स हिंदुजा हाउसिंग फाइनेंस लिमिटेड के प्राधिकृत अधिकारी होने के नाते उधारकर्ता (ओं) और सह–उधारकर्ता (ओं) को फ्लैट नं एसएफ –02, एलआईजी फ्रंट साइड, छत के अधिकारों के साथ दूसरी मंजिल, 50 वर्ग गज मापने वाला क्षेत्र, प्लॉट नंबर 16, खसरा नंबर 355, संत नगर, लोनी, गाजियाबादमें रखी गई संपत्ति में रखे चल सामान को एकत्र करने के लिए यह नोटिस जारी कर रहे है। जो पूर्व की ओर भूखंड के शेष भाग से घिरा हुआ है, पश्चिम की ओर दिगार मलिक, उत्तर की ओर 20 फीट चौड़ी सड़क और दक्षिण की ओर एक स्कूल, जिसकी सूची अदालत द्वारा नियुक्त रिसीवर द्वारा तैयार की गई है।

उपरोक्त के संबंध में सूचना एतद्द्वारा उधारकर्ता (ओं)और सह–उधारकर्ता (ओं) को 14.02.2024 को सुबह 12 बजे से दोपहर 2 बजे के बीच उपरोक्त संपत्ति से अपना चल सामान/सामान एकत्र करने के लिए दिया गया है। आप आगे नोट कर सकते हैं कि उधारकर्ता(ओं) और सह–उधारकर्ता(ओं) की ओर से उक्त वस्तुओं को एकत्र करने में विफलता की स्थिति में, अधोहस्ताक्षरी उक्त वस्तुओं के स्वास्थ्य और रखरखाव के संबंध में किसी भी तरह से जिम्मेदार नहीं होगा और इसे तीसरे पक्ष को बेचा जाएगा और चल वस्तुओं की बिक्री से प्राप्त राशि को ऋण बकाया ऋण खाता संख्या DL/DEL/DLHI/A000000124 के साथ समायोजित किया जाएगा।
अधिकृत अधिकारी
दिनांक : 09.02.2024 हिंदुजा हाउसिंग फाइनेंस लिमिटेड के लिए
स्थान : दिल्ली

YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED
Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India
Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India
Website: www.yatharthhospitals.com Email: cs@yatharthhospitals.com CIN : L85110DL2008PLC174706

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2023

Rs. in Million except Shares and EPS

S. No.	Particulars	Consolidated					
		Quarter Ended			Nine Month Ended		Year Ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	1,667.93	1,712.80	1,375.45	4,925.80	3,765.01	5,202.93
2	Profit / (loss) before exceptional items and tax (III-IV)	437.82	395.70	240.25	1,127.21	627.37	876.78
3	Profit / (loss) before tax (V-VI)	437.82	395.70	240.25	1,127.21	627.37	876.78
4	Total tax (VIII)	142.94	119.68	27.71	365.94	142.88	219.10
5	Net Profit/(loss) after tax (VII-VIII)	276.03	190.36	161.99	466.39	271.95	657.68
6	Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	294.88	276.03	215.58	761.26	487.73	660.80
7	Earnings Per Share (Rs.10 each) (Not annualised except for the year ended 31 March 2023)						
	Basic	3.83	3.80	3.04	9.88	7.44	10.09
	Diluted	3.83	3.80	3.04	9.88	7.44	10.09

NOTES :-
1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 February ,2024.
2) The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com, NSE at www.nseindia.com and on the Company's website at www.yatharthhospitals.com/investors.
3) The above results of the Company have been limited reviewed by the Statutory Auditors and they have issued an unqualified opinion on the same.
4) Previous figures have been regrouped/ rearranged / reclassified, wherever necessary.

For and on behalf of
Yatharth Hospital & Trauma Care Sevices Ltd
Dr. Ajay Kumar Tyagi
Chairman and whole-time Director
DIN:01792886

Place : Noida
Date : 10.02.2024

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Initial public offer of Equity Shares (as defined below) on the main board of the Stock Exchanges (defined below) in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended

PUBLIC ANNOUNCEMENT

Akums

AKUMS DRUGS AND PHARMACEUTICALS LIMITED

(Please scan this QR code to view the DRHP)

Our Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of 'Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("**RoC**"). Our Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Registered Office: 304, Mohan Place, LSC Saraswati Vihar, Delhi – 110 034, India
Corporate Office: Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area, Phase 1, Delhi – 110 083, India
Telephone: + 91 11 6904 1000; **Contact person:** Dharamvir Malik, Company Secretary and Compliance Officer
E-mail: cs@akums.net; **Website:** www.akums.in; **Corporate Identity Number:** U24239DL2004PLC125888

THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST

INITIAL PUBLIC OFFER OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [•] MILLION COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹ 6,800 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 18,598,365 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, COMPRISING UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANJEEV JAIN, UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANDEEP JAIN (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO 14,306,435 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

THIS OFFER INCLUDES A RESERVATION OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹[•] MILLION FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE [•]% AND [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.

OUR COMPANY, IN CONSULTATION WITH THE BRLMs, MAY CONSIDER A PRIVATE PLACEMENT OF UP TO 20% OF THE FRESH ISSUE OR SUCH OTHER AMOUNT AS MAY BE ALLOWED UNDER APPLICABLE LAW FOR CASH CONSIDERATION AGGREGATING UP TO ₹ 1,360 MILLION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE MINIMUM OFFER SIZE (COMPRISING THE FRESH ISSUE SO REDUCED BY THE AMOUNT RAISED FROM THE PRE-IPO PLACEMENT, AND THE OFFER FOR SALE) SHALL CONSTITUTE AT LEAST 10% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 2 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [•], AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF [•], A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE AND NSE (TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.

In case of any revision to the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Managers, for reasons to be recorded in writing, may extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("**SCSBs**"), other Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**") ("**QIB Portion**"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price ("**Anchor Investor Portion**"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA accounts and UPI ID (in case of UPI Bidders) (as defined hereinafter), in which case the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or under the UPI Mechanism, as applicable to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "*Offer Procedure*" on page 415 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares pursuant to the Offer and has filed the DRHP dated February 10, 2024 with the Securities and Exchange Board of India ("**SEBI**") on February 11, 2024.

Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made available to the public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the Book Running Lead Managers ("BRLMs"), i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and www.ambit.co, respectively. Our Company hereby invites the public to provide comments on the DRHP filed with SEBI, with respect to disclosures made therein. The public is requested to send a copy of the comments to SEBI, to the Company Secretary & Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein below. All comments must be received by SEBI and/or our Company and/or the Company Secretary & Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5.00 p.m. on the 21st day from the aforesaid date of filing the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the section titled "*Risk Factors*" of the RHP, once available, carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" on page 27 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after a red herring prospectus ("**RHP**") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the Stock Exchanges.

The liability of the members of our Company is limited. For details of the share capital and capital structure of our Company and the name of the signatories to its Memorandum of Association and the number of shares subscribed by them of our Company, please see "*Capital Structure*" on page 72 of the DRHP. For details of the main objects of our Company as contained in its Memorandum of Association, please see "*History and Certain Corporate Matters*" on page 204 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
ICICI Securities	AXIS CAPITAL	citi	AMBIT Acumen at work	LINKIntime
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India **Tel:** +91 22 6807 7100 **E-mail:** akums.ipo@icicisecurities.com **Investor grievance e-mail:** customercare@icicisecurities.com **Website:** www.icicisecurities.com **Contact Person:** Namrata Ravasia / Harsh Thakkar **SEBI Registration No.:** INM000011179	**Axis Capital Limited** 1st Floor, Axis House, C-2 Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai 400 025, Maharashtra, India **Tel:** +91 22 4325 2183 **E-mail:** akums.ipo@axiscap.in **Investor grievance e-mail:** complaints@axiscap.in **Website:** www.axiscapital.co.in **Contact Person:** Akash Aggarwal / Jigar Jain **SEBI Registration No.:** INM000012029	**Citigroup Global Markets India Private Limited** 1202, 12th Floor, First International Financial Centre, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 098, Maharashtra, India **Tel:** +91 22 6175 9999 **E-mail:** akums.ipo@citi.com **Website:** www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm **Investor Grievance ID:** investors.cgmib@citi.com **Contact Person:** Abhishek Mawandiya **SEBI Registration Number:** INM000010718	**Ambit Private Limited** Ambit House, 449, Senapati Bapat Marg, Lower Parel, Mumbai 400 013 Maharashtra, India **Tel:** + 91 22 6623 3030 **E-mail:** akums.ipo@ambit.co **Investor Grievance E-mail:** customerservicemb@ambit.co **Website:** www.ambit.co **Contact person:** Siddhesh Deshmukh **SEBI registration number:** INM000010585	**Link Intime India Private Limited** C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India **Tel:** +91 810 811 4949 **E-mail:** akumsdrugs.ipo@linkintime.co.in **Website:** www.linkintime.co.in **Investor Grievance ID:** akumsdrugs.ipo@linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **SEBI Registration Number:** INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **AKUMS DRUGS AND PHARMACEUTICALS LIMITED**

On behalf of the Board of Directors
Sd/-
Dharamvir Malik
Company Secretary & Compliance Officer

Place: New Delhi
Date: February 11, 2024

AKUMS DRUGS AND PHARMACEUTICALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP with SEBI on February 11, 2024. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the BRLMs, i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and www.ambit.co, respectively. Potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "*Risk Factors*" of the RHP, once filed. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision and must rely on their own examination of our Company and the Offer, including the risks involved.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of securities in the United States.

Adfactors

www.readwhere.com